Cetuximab sarotalocan - Rakuten Medical
Alternative Names: Akalux; ASP-1929; Cetuximab-IR700; RM-1929Latest Information Update: 20 May 2024
At a glance
- Originator Aspyrian Therapeutics
- Developer National Cancer Center Hospital East; Rakuten Medical
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Cell death stimulants; Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Head and neck cancer
- Phase II Squamous cell cancer
- Phase I Oesophageal cancer
- Preclinical Cancer
- No development reported Gastric cancer
Most Recent Events
- 29 Mar 2024 Rakuten Medical terminates a phase II trial in Squamous cell cancer (Combination therapy, Recurrent, Second-line therapy or greater) in Taiwan (IV) due to business decision (NCT05265013)
- 22 Jan 2024 Phase-III clinical trials in Head and neck cancer (Inoperable/Unresectable, Late-stage disease, Recurrent, Second-line therapy or greater) in India (IV) (NCT03769506)
- 10 Aug 2023 Rakuten Medical and Hikma Pharmaceuticals enters into a marketing agreement to commercialize in Middle East and North Africa